525 related articles for article (PubMed ID: 17056720)
21. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog.
Reubi JC; Erchegyi J; Cescato R; Waser B; Rivier JE
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1551-8. PubMed ID: 20396884
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs.
Cervia D; Nunn C; Fehlmann D; Langenegger D; Schuepbach E; Hoyer D
Br J Pharmacol; 2003 May; 139(1):109-21. PubMed ID: 12746229
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a New
Mansi R; Nicolas GP; Del Pozzo L; Abid KA; Grouzmann E; Fani M
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932783
[TBL] [Abstract][Full Text] [Related]
24. Somatostatin Receptor Antagonists for Imaging and Therapy.
Fani M; Nicolas GP; Wild D
J Nucl Med; 2017 Sep; 58(Suppl 2):61S-66S. PubMed ID: 28864614
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
26. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry.
Schottelius M; Rau F; Reubi JC; Schwaiger M; Wester HJ
Bioconjug Chem; 2005; 16(2):429-37. PubMed ID: 15769098
[TBL] [Abstract][Full Text] [Related]
27. Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.
Waser B; Cescato R; Tamma ML; Maecke HR; Reubi JC
Eur J Pharmacol; 2010 Oct; 644(1-3):257-62. PubMed ID: 20643121
[TBL] [Abstract][Full Text] [Related]
28. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.
Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR
PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724
[TBL] [Abstract][Full Text] [Related]
29. Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity.
Grace CR; Erchegyi J; Samant M; Cescato R; Piccand V; Riek R; Reubi JC; Rivier JE
J Med Chem; 2008 May; 51(9):2676-81. PubMed ID: 18410083
[TBL] [Abstract][Full Text] [Related]
30. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
[TBL] [Abstract][Full Text] [Related]
32. Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist.
Rajeswaran WG; Hocart SJ; Murphy WA; Taylor JE; Coy DH
J Med Chem; 2001 Apr; 44(8):1305-11. PubMed ID: 11312929
[TBL] [Abstract][Full Text] [Related]
33. Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.
Heppeler A; André JP; Buschmann I; Wang X; Reubi JC; Hennig M; Kaden TA; Maecke HR
Chemistry; 2008; 14(10):3026-34. PubMed ID: 18246556
[TBL] [Abstract][Full Text] [Related]
34. Highly potent cyclic disulfide antagonists of somatostatin.
Hocart SJ; Jain R; Murphy WA; Taylor JE; Coy DH
J Med Chem; 1999 Jun; 42(11):1863-71. PubMed ID: 10354394
[TBL] [Abstract][Full Text] [Related]
35. SST3-selective potent peptidic somatostatin receptor antagonists.
Reubi JC; Schaer JC; Wenger S; Hoeger C; Erchegyi J; Waser B; Rivier J
Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13973-8. PubMed ID: 11095748
[TBL] [Abstract][Full Text] [Related]
36. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
